Skip to main content

Advertisement

SpringerLink
Log in

Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This was an exploratory analysis comparing the safety and efficacy of immunoadsorption (IAS) combination therapy in severe systemic lupus erythematosus (SLE) receiving corticosteroid pulse and immunosuppressant treatment. Patients enrolled all had predominant organ involvement including proteinuria, thrombocytopenia, pericardial effusion, and cerebral involvement requiring corticosteroid pulse treatment. Fifty-two patients in study group received IAS plus corticosteroid and cyclophosphamide treatment. Fifty-two patients in non-IAS group received corticosteroid and cyclophosphamide treatment. Outcome measurement included C3, dsDNA, AnuA, and SLE disease activity index (SLEDAI) 2k score and in particular cases, proteinuria quantification and platelet count. Disease activity dropped significantly in both groups. Improvement of disease activity markers was more significant in study group than that in non-IAS group. The lower dosage of steroid in study group suggested the steroid-sparing effect of IAS. No severe adverse effect occurred during IAS. Our study suggested IAS as an additional therapy to steroid pulse and immunosuppressant in treating severe SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wener MH (2007) Immune complexes in systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus, 1st edn. Mosby, Philadelphia, pp 214–224

    Chapter  Google Scholar 

  2. Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci 1051:635–646, PubMed: 16127004

    Article  CAS  PubMed  Google Scholar 

  3. Stummvoll GH (2011) Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus 20(2):115–119, PubMed: 21303827

    Article  CAS  PubMed  Google Scholar 

  4. Loo CY, Mohamed Said MS, Mohd R, Abdul Gafor AH, Saidin R, Halim NA et al (2010) Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci 43(3):335–340

    Article  PubMed  Google Scholar 

  5. Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P (2012) Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant 27(2):618–626, PubMed: 21617196

    Article  CAS  PubMed  Google Scholar 

  6. Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Hörl WH et al (2005) IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 64(7):1015–1021, PubMed: 15640267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Biesenbach P, Schmaldienst S, Smolen JS, Hörl WH, Derfler K, Stummvoll GH (2009) Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atheroscler Suppl 29; 10(5):114–121

    Article  Google Scholar 

  8. Amital H, Heilweil-Harel M, Ulmansky R, Harlev M, Toubi E, Hershko A et al (2007) Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption. Rheumatology 46:1433–1437, PubMed: 17686790

    Article  CAS  PubMed  Google Scholar 

  9. Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F (2001) Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 44(8):1962–1963, PubMed: 11508450

    Article  CAS  PubMed  Google Scholar 

  10. Berner B, Scheel AK, Schettler V, Hummel KM, Reuss-Borst MA, Müller GA et al (2001) Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 60(9):898–899, PubMed: 11534506

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Funauchi M, Ikoma S, Enomoto H, Ohno M, Kinoshita K, Horiuchi A et al (1996) High-affinity anti-DNA antibody parallels clinical course of immunoadsorption therapy. Intern Med 35(5):367–372, PubMed: 8797048

    Article  CAS  PubMed  Google Scholar 

  12. Kinoshita M, Aotsuka S, Funahashi T, Tani N, Yokohari R (1989) Selective removal of anti-double-stranded DNA antibodies by immunoadsorption with dextran sulphate in a patient with systemic lupus erythematosus. Ann Rheum Dis 48(10):856–860, PubMed: 2479345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sugimoto K, Yamaji K, Yang KS, Kanai Y, Tsuda H, Hashimoto H (2006) Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial 10(2):187–192, PubMed: 16684222

    Article  CAS  PubMed  Google Scholar 

  14. Gaubitz M, Seidel M, Kummer S, Schotte H, Perniok A, Domschke W et al (1998) Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 11:495–501, PubMed: 9802935

    Article  CAS  PubMed  Google Scholar 

  15. Schneider M, Berning T, Waldendorf M, Glaser J, Gerlach U (1990) Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus. J Rheumatol 17(7):900–907, PubMed: 2213756

    CAS  PubMed  Google Scholar 

  16. Yamazaki Z, Idezuki Y, Inoue N, Yoshizawa H, Yamawaki N, Inagaki K et al (1989) Extracorporral imuunoadsorption with IM-PH or IM-TR column. Biomater Artif Cells Artif Organs 17(2):117–124, PubMed: 2673426

    Article  CAS  PubMed  Google Scholar 

  17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277, PubMed: 7138600

    Article  CAS  PubMed  Google Scholar 

  18. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725, PubMed: 9324032

    Article  CAS  PubMed  Google Scholar 

  19. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686, PubMed: 22553077

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64(6):797–808, PubMed: 22556106

    Article  Google Scholar 

  21. Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291, PubMed: 11838846

    PubMed  Google Scholar 

  22. Badsha H, Kong KO, Lian TY, Chan SP, Edwards CJ, Chng HH (2002) Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 11(8):508–513, PubMed: 12220105

    Article  CAS  PubMed  Google Scholar 

  23. Kong KO, Badsha H, Lian TY, Edwards CJ, Chng HH (2004) Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 13(3):212–213, PubMed: 15119552

    Article  CAS  PubMed  Google Scholar 

  24. Suzuki K (2000) The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther Apher 4(3):239–243, PubMed: 10910027

    Article  CAS  PubMed  Google Scholar 

  25. Graninger M, Schmaldienst S, Derfler K, Graninger WB (2002) Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 29(1):26–29, PubMed: 11899750

    Article  PubMed  Google Scholar 

  26. Suzuki K, Hara M, Harigai M, Ishizuka T, Hirose T, Matsuki Y, Kawaguchi Y et al (1991) Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 34(12):1546–1552, PubMed: 1747139

    Article  CAS  PubMed  Google Scholar 

  27. Braun N, Jünger M, Klein R, Gutenberger S, Guagnin M, Risler T (2002) Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. Ther Apher 6(6):471–477, PubMed: 12460414

    Article  PubMed  Google Scholar 

  28. Stefanutti C, Vivenzio A, Di Giacomo S, Mareri M, Ceccarelli F, Valesini G (2005) Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonresponsive to drug therapy alone. BioDrugs 19(2):129–133, PubMed: 15807630

    Article  CAS  PubMed  Google Scholar 

  29. Palmer A, Cairns T, Dische F, Gluck G, Gjorstrup P, Parsons V et al (1991) Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 6(8):536–542, PubMed: 1956551

    Article  CAS  PubMed  Google Scholar 

  30. Schmaldienst S, Müllner M, Goldammer A, Spitzauer S, Banyai S, Hörl WH et al (2001) Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 40(5):513–521

    Article  CAS  Google Scholar 

  31. Takahashi S, Wada N, Harada K (2007) Immunoadsorbent apheresis eliminates pathogenic IgG in childhood lupus nephritis. Pediatr Int 49(6):817–821, PubMed: 18045278

    Article  CAS  PubMed  Google Scholar 

  32. Lhotta K, Würzner R, Rosenkranz AR, Beer R, Rudisch A, Neumair F et al (2004) Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus 13(2):139–141, PubMed: 14995009

    Article  CAS  PubMed  Google Scholar 

  33. Dittrich E, Schmaldienst S, Langer M, Jansen M, Hörl WH, Derfler K (2002) Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res 25(4):232–239, PubMed: 12424425

    Article  CAS  PubMed  Google Scholar 

  34. Stummvoll GH, Aringer M, Jansen M, Smolen JS, Derfler K, Graninger WB (2004) Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr 116(21-22):716–724, PubMed: 15628641

    Article  PubMed  Google Scholar 

  35. Taniguchi Y, Yorioka N, Okushin S, Oda H, Usui K, Yamakido M (1995) Usefulness of immunoadsorption therapy for systemic lupus erythematosus associated with transverse myelitis. A case report. Int J Artif Organs 18(12):799–801, PubMed: 8964648

    CAS  PubMed  Google Scholar 

  36. Hershko AY, Scheiman-Elazari A, Aamar S, Naparstek Y (2013) Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study. Immunol Res 56(2-3):376–381, PubMed: 23584986

    Article  CAS  PubMed  Google Scholar 

  37. Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z et al (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 93(26), e143, PubMed:25474424

    Article  CAS  Google Scholar 

  38. Ross S, Benz K, Sauerstein K, Amann K, Dötsch J, Dittrich K (2012) Unexpected recovery from longterm renal failure in severe diffuse proliferative lupus nephritis. BMC Nephrol 13:81, PubMed: 2286727

  39. Rech J, Hueber AJ, Kallert S, Requadt C, Kalden JR, Schulze-Koops H (2006) Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency. Ann Rheum Dis 65(4):552–553, PubMed: 16531554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Stummvoll GH, Julius U, Derfler K, Aringer M (2009) Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl 10(5):110–113, PubMed: 20129387

    Article  CAS  PubMed  Google Scholar 

  41. Hauser AC, Hauser L, Pabinger-Fasching I, Quehenberger P, Derfler K, Hörl WH (2005) The course of anticardiolipin antibody levels under immunoadsorption therapy. Am J Kidney Dis 46(3):446–454, PubMed: 16129206

    Article  CAS  PubMed  Google Scholar 

  42. Maeshima E, Yamada Y, Kodama N, Mune M, Yukawa S (1999) Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporin A. Scand J Rheumatol 28(1):54–57, PubMed: 10092166

    Article  CAS  PubMed  Google Scholar 

  43. Schmaldienst S, Jansen M, Hollenstein U, Graninger W, Regele H, Hörl WH et al (2002) Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 39:415–418, PubMed: 11840385

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the nursing team of the apheresis unit for the accurate and friendly support. This research was supported by a National grant (81301529).

Author information

Authors and Affiliations

  1. Rheumatology Department, The Fourth People’s Hospital of Shenzhen, Shenzhen, China

    Jinxian Huang, Zhihua Yin, Weizhen He, Weihong Kong & Zhizhong Ye

  2. Rheumatology Department, The University of Hong Kong-Shenzhen Hospital, Haiyuan Road, Shenzhen, 518000, China

    Jinxian Huang & Lijun Zhang

  3. The Third People’s Hospital of Shenzhen, Shenzhen, China

    Guoxiang Song

Authors
  1. Jinxian Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guoxiang Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihua Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weizhen He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lijun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weihong Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhizhong Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinxian Huang.

Ethics declarations

All patients signed informed consent. The study was approved by the local ethics committee.

Disclosures

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 54 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, J., Song, G., Yin, Z. et al. Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus. Clin Rheumatol 35, 2211–2218 (2016). https://doi.org/10.1007/s10067-016-3354-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3354-2

Keywords

Search

Navigation